| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Alembic Pharms. Ltd. v. Daiichi Sankyo Co., Ltd., 16-3956 (N.D. Ill.) | Apr. 1, 2016 | Hon. John Z. Lee | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
| Merck Sharp & Dohme Corp. v. Roxane Labs., Inc., 16-0285 (S.D. Ohio) | Apr. 1, 2016 | Hon. James L. Graham | Noxafil® (posaconazole oral suspension) |
5,661,151
6,958,337
|
| Warner Chilcott (US), LLC v. Zydus Pharms. (USA) Inc., 16-0323 (E.D. Tex.) | Apr. 1, 2016 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00829 (PTAB) | Apr. 1, 2016 | N/A | Ravicti® (glycerol phenylbutyrate oral solution) | 9.095.559 |
| Millennium Pharms., Inc. v. Actavis LLC, 16-0223 (D. Del.) | Apr. 4, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446 |
| Javelin Pharms., Inc. v. Mylan Labs. Ltd., 16-0224 (D. Del.) | Apr. 4, 2016 | Hon. Leonard P. Stark | Dyloject® (diclofenac sodium for injection) |
6,407,079
8,946,292
|
| Abraxis Bioscience, LLC v. Actavis LLC, 16-1925 (D.N.J.) | Apr. 6, 2016 | Hon. John Michael Vazquez | Abraxane® (albumin-bound paclitaxel for injection) |
7,820,788
7,923,536
8,138,229
8,853,260
|
| Javelin Pharms., Inc. v. Mylan Labs. Ltd., 16-0059 (N.D.W.V.) | Apr. 6, 2016 | Hon. Irene M. Keeley | Dyloject® (diclofenac sodium for injection) |
6,407,079
8,946,292
|
| Acura Pharms., Inc. v. Purdue Pharma L.P., IPR2016-00849 (PTAB) | Apr. 6, 2016 | N/A | OxyContin® (oxycodone tablets) | 8,389,007 |
| Fresenius Kabi USA, LLC v. Maia Pharms., Inc., 16-0237 (D. Del.) | Apr. 7, 2016 | Hon. Gregory M. Sleet | Levothyroxine Sodium (levothyroxine sodium for injection) |
9,006,289
9,168,238
9,168,239
|
| Alcon Research, Ltd. v. Watson Labs., Inc., 16-0238 (D. Del.) | Apr. 7, 2016 | Hon. Richard G. Andrews | Izba® (travoprost ophthalmic solution) |
8,178,582
8,722,735
8,754,123
9,144,561
|
| AstraZeneca Pharms. LP v. InnoPharma Licensing LLC, 16-1962 (D.N.J.) | Apr. 7, 2016 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Bayer Intellectual Property GMBH v. Micro Labs Ltd., 16-0242 (D. Del.) | Apr. 8, 2016 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,585,860
7,592,339
|
| Takeda Pharm. Co. Ltd. v. Teva Pharms. USA, Inc., 16-0246 (D. Del.) | Apr. 8, 2016 | Hon. Leonard P. Stark | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
| Upsher-Smith Labs., Inc. v. Zydus Pharms. (USA) Inc., 16-0248 (D. Del.) | Apr. 8, 2016 | Hon. Sue L. Robinson | Qudexy® XR (topiramate extended-release capsules) |
8,652,527
8,889,190
9,101,545
|
| Fresenius Kabi USA, LLC v. B. Braun Medical Inc., 16-0250 (D. Del.) | Apr. 11, 2016 | Hon. Richard G. Andrews | Diprivan® (propofol for injection) | 8,476,010 |
| Allergan, Inc. v. Famy Care Ltd., 16-0401 (E.D. Tex.) | Apr. 12, 2016 | Hon. Rodney Gilstrap | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
9,248,191
|
| Takeda GMBH v. Torrent Pharma Inc., 16-1280 (D.N.J.) | Apr. 13, 2016 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| Galderma Labs., L.P. v. Akorn, Inc., 16-1012 (N.D. Tex.) | Apr. 14, 2016 | Hon. David C Godbey | Clobex® (clobetasol propionate spray) | 5,972,920 |
| Forest Labs., LLC v. Apotex Corp., 16-0269 (D. Del.) | Apr. 15, 2016 | Hon. Gregory M. Sleet | Teflaro® (ceftaroline fosamil injection) | 6,417,175 |
| Teva Pharms. USA, Inc. v. Biocon Ltd., 16-0278 (D. Del.) | Apr. 19, 2016 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate injection) |
8,232,250
8,399,413
8,969,302
9,155,776
|
| Sanofi-Aventis U.S. LLC v. Dr. Reddy's Labs., Inc., 16-2259 (D.N.J.) | Apr. 21, 2016 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel solution for infusion) | 5,847,170 |
| Novartis AG v. Mylan Pharms. Inc., 16-0289 (D. Del.) | Apr. 22, 2016 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 5,604,229 |
| Senju Pharm. Co., Ltd. v. Hi-tech Pharmacal Co., Inc., 16-2270 (D.N.J.) | Apr. 22, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
9,144,609
|
| Par Pharm., Inc. v. Luitpold Pharms., Inc., 16-2290 (D.N.J.) | Apr. 22, 2016 | Hon. William H. Walls | Adrenalin® (epinephrine injection) |
9,119,876
9,295,657
|
| Par Pharm., Inc. v. Luitpold Pharms., Inc., 16-1999 (E.D.N.Y.) | Apr. 22, 2016 | Hon. Ann M Donnelly | Adrenalin® (epinephrine injection) |
9,119,876
9,295,657
|
| Galderma Labs., L.P. v. Tolmar Inc., 16-1099 (N.D. Tex.) | Apr. 22, 2016 | Hon. David C Godbey | Epiduo® (adapalene and benzoyl peroxide gel) |
8,071,644
8,080,537
8,129,362
8,445,543
8,809,305
|
| Amneal Pharms. LLC v. GlaxoSmithKline LLC, 16-0300 (D. Del.) | Apr. 25, 2016 | Hon. Sue L. Robinson | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
| Boehringer Ingelheim Pharma GMBH & Co. KG v. Hetero USA, Inc., 16-2356 (D.N.J.) | Apr. 26, 2016 | Hon. Mary L. Cooper | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Boehringer Ingelheim Pharms. Inc. v. Dr. Reddy's Labs., Ltd., 16-2394 (D.N.J.) | Apr. 28, 2016 | Hon. Peter G. Sheridan |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
9,173,859 |
| AstraZeneca AB v. Hetero USA Inc., 16-2442 (D.N.J.) | Apr. 29, 2016 | Hon. Mary L. Cooper | Nexium® 24HR (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
| Aurobindo Pharms. Ltd. v. Daiichi Sankyo, Inc., 16-4876 (N.D. Ill.) | May 2, 2016 | Hon. Rebecca R. Pallmeyer |
Benicar® (olmesartan medoxomil tablets)
Benicar HZT® (olmesartan medoxomil / hydrochlorothiazide tablets)
|
6,878,703 |
| BTG International Ltd. v. Amerigen Pharms., Inc., 16-2449 (D.N.J.) | May 2, 2016 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-2475 (D.N.J.) | May 2, 2016 | Hon. Jerome B. Simandle, | Abilify® (aripiprazole tablets) | 8,759,350 |
| Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-2476 (D.N.J.) | May 2, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Endo Pharms. Inc. v. Impax Labs., Inc., 16-2526 (D.N.J.) | May 4, 2016 | Hon. Jose L. Linares | Opana® ER (extended-release oxymorphone hydrochloride) |
8,309,122
8,329,216
8,808,737
|
| Leo Pharma A/S v. Actavis Labs. UT, Inc., 16-0333 (D. Del.) | May 6, 2016 | Hon. Sue L. Robinson | Picato® (ingenol mebutate gel) |
7,410,656
8,278,292
8,372,827
8,372,828
8,377,919
8,536,163
8,716,271
8,735,375
|
| AstraZeneca LP v. Watson Labs., Inc., 16-0338 | May 9, 2016 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,525,060
7,250,419
7,265,124
|
| Breckenridge Pharm., Inc. v. Novartis AG, IPR2016-01023 (PTAB) | May 10, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
| Rhodes Pharms. L.P. v. Actavis, Inc., 16-2667 (D.N.J.) | May 11, 2016 | Hon. William H. Walls | Aptensio XR® (methylphenidate hydrochloride extended-release capsules) |
6,419,960
7,083,808
7,247,318
7,438,930
8,580,310
9,066,869
|
| Mylan Institutional LLC v. Aurobindo Pharma Ltd., 16-0491 (E.D. Tex.) | May 11, 2016 | Hon. Robert W. Schroeder, III | Isosulfan blue (isosulfan blue) |
7,662,992
8,969,616
|
| Amneal Pharma. LLC v. Purdue Pharma L.P., IPR2016-01027 (PTAB) | May 11, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,060,976 |
| Amneal Pharma. LLC v. Purdue Pharma L.P., IPR2016-01028 (PTAB) | May 11, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,060,976 |
| Wockhardt Bio AG v. AstraZeneca AB, IPR2016-01029 (PTAB) | May 11, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
| Mylan Pharms Inc. v. Shire Labs., Inc., IPR2016-01033 (PTAB) | May 12, 2016 | N/A | Adderall® XR (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | RE42,096 |
| Santen Pharm. Co., Ltd. v. Micro Labs Ltd., 16-0353 (D. Del.) | May 13, 2016 | Hon. Gregory M. Sleet | Zioptan® (tafluprost ophthalmic solution) | 5,886,035 |
| Santen Pharm. Co., Ltd. v. Sandoz Inc., 16-0354 (D. Del.) | May 13, 2016 | Hon. Gregory M. Sleet | Zioptan® (tafluprost ophthalmic solution) | 5,886,035 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-01059 (PTAB) | May 17, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
| ApoPharma Inc. v. Taro Pharm. Indus., Ltd., 16-0528 (E.D. Tex.) | May 18, 2016 | Hon. Robert W. Schroeder, III | Ferriprox® (deferiprone tablets) | 7,049,328 |
| Novartis AG v. Mylan Pharms. Inc., 16-0093 (N.D.W.V.) | May 18, 2016 | Hon. Irene M. Keeley | Gilenya® (fingolimod capsules) | 5,604,229 |
| Forest Labs., LLC v. Accord Healthcare, Inc., 16-0375 (D. Del.) | May 20, 2016 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009
8,058,291
8,168,209
8,173,708
8,283,379
8,293,794
8,329,752
8,338,485
8,338,486
8,362,085
8,580,858
8,598,233
|
| Lotus Pharm. Co., Ltd. v. GlaxoSmithKline LLC, 16-0377 (D. Del.) | May 20, 2016 | Hon. Gregory M. Sleet | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
| Mylan Pharms., Inc. v. Research Corp. Technologies, Inc., IPR2016-01101 (PTAB) | May 25, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
| Allergan, Inc. v. Somerset Therapeutics, LLC, 16-0392 (D. Del.) | May 26, 2016 | Hon. Gregory M. Sleet | Lastacaft® (alcaftadine ophthalmic solution) | 8,664,215 |
| Roxane Labs., Inc. v. Novartis AG, IPR2016-01102 (PTAB) | May 26, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
| Breckenridge Pharm., Inc. v. Novartis AG, IPR2016-01103 (PTAB) | May 26, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
| Alvogen Pine Brook LLC v. Noven Pharms., Inc., 16-0395 | May 27, 2016 | Hon. Leonard P. Stark | Minivelle® (estradiol extended-release film) |
6,841,716
8,231,906
|
| Orexo AB v. Actavis Elizabeth LLC, 16-0397 (D. Del.) | May 27, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride sublingual tablets) | 9,259,421 |
| AbbVie Inc. v. Amneal Pharms., LLC, 16-0398 (D. Del.) | May 27, 2016 | Hon. Richard G. Andrews | Norvir® (ritonavir tablets) |
7,148,359
7,364,752
|
| Luye Pharma Group Ltd. v. Alkermes Pharma Ireland Ltd, IPR2016-01095 (PTAB) | May 31, 2016 | N/A |
Bydureon® (exenatide synthetic extended-release suspension)
Vivitrol® (naltrexone extended-release suspension)
Risperdal® (risperidone for injection)
|
6,667,061 |
| Luye Pharma Group Ltd. v. Alkermes Pharma Ireland Ltd, IPR2016-01096 (PTAB) | May 31, 2016 | N/A |
Bydureon® (exenatide synthetic extended-release suspension)
Vivitrol® (naltrexone extended-release suspension)
Risperdal® (risperidone for injection)
|
6,667,061 |
| Dr. Reddyy's Labs., Ltd v. MonoSol RX, LLC, IPR2016-01111 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,603,514 |
| Dr. Reddyy's Labs., Ltd v. MonoSol RX, LLC, IPR2016-01112 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,017,150 |
| Dr. Reddyy's Labs., Ltd v. Indivior UK Limited f/k/a RB Pharms. Ltd., IPR2016-01113 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,475,832 |
| Sun Pharm. Indus., Ltd. v. AstraZeneca AB, IPR2016-01104 (PTAB) | June 1, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
| Teva Pharms. USA, Inc. v. AstraZeneca AB, IPR2016-01122 (PTAB) | June 1, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
| Aurobindo Pharma U.S.A., Inc. v. AstraZeneca AB, IPR2016-01117 (PTAB) | June 2, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
| Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01127 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,685,930 |
| Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01128 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 |
| Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01129 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,642,556 |
| Mylan Pharms. Inc. v. Allergan, Inc., IR2016-01130 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,633,162 |
| Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01131 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,648,048 |
| Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01132 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 9,248,191 |
| Mylan Pharms., Inc. v. Senju Pharm. Co., Ltd., IPR2016-01163 (PTAB) | June 8, 2016 | N/A | Bepreve® (bepotastine besilate ophthalmic solution) | 8,877,168 |
| Aurobindo Pharma USA Inc. v. Apicore US LLC, 16-3358 (D.N.J.) | June 9, 2016 | Hon. Renee Marie Bumb | Isosulfan blue (isosulfan blue) |
7,662,992
8,969,616
9,353,050
|
| Leo Pharma A/S v. Perrigo UK Finco Ltd. Partnership, 16-0430 (D. Del.) | June 10, 2016 | Hon. Sue L. Robinson | Picato® (ingenol mebutate gel) |
6,432,452
6,787,161
6,844,013
7,410,656
8,278,292
8,372,827
8,372,828
8,377,919
8,536,163
8,716,271
8,735,375
|
| Novartis Pharms. Corp. v. Breckenridge Pharm., Inc., 16-0431 (D. Del.) | June 10, 2016 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
8,410,131
8,778,962
|
| Purdue Pharma L. P. v. Collegium Pharm., Inc., 16-11091 (D. Mass.) | June 10, 2016 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone)
Xtampza ER™ (oxycodone)
|
9,155,717 |
| UCB, Inc. v. Aurobindo Pharma Ltd., 16-0451 (D. Del.) | June 17, 2016 | Hon. Leonard P. Stark | Vimpat® (lacosamide) | RE38,551 |
| UCB, Inc. v. Hetero USA Inc., 16-0452 (D. Del.) | June 17, 2016 | Hon. Leonard P. Stark | Vimpat® (lacosamide) | RE38,551 |
| Shire Orphan Therapies LLC v. InnoPharma, Inc., 16-0456 (D. Del.) | June 17, 2016 | Hon. Gregory M. Sleet | Firazyr® (icatibant for injection) | 5,648,333 |
| United Therapeutics Corp. v. Actavis Labs. FL, Inc., 16-3642 (D.N.J.) | June 17, 2016 | Hon. Peter G. Sheridan | Orenitram® (treprostinil extended-release tablets) |
7,417,070
7,544,713
8,252,839
8,349,892
8,410,169
8,497,393
9,050,311
8,747,897
9,278,901
|
| Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 16-0465 (D. Del.) | June 20, 2016 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 8,231,906 |
| Eli Lilly and Co. v. Apotex Inc., 16-1512 (S.D. Ind.) | June 20, 2016 | Hon. William T. Lawrence | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
9,180,194
9,289,586
|
| Breckenridge Pharm., Inc. v. Research Corp. Technologies, Inc., IPR2016-01242 (PTAB) | June 21, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
| Eli Lilly and Co. v. Apotex Inc., 16-0475 (D. Del.) | June 22, 2016 | Hon. Leonard P. Stark | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
9,180,194
9,289,586
|
| Argentum Pharms. LLC v. Allergan, Inc., IPR2016-01232 (PTAB) | June 22, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 |
| Alembic Pharms., Ltd.v. Research Corp. Technologies, Inc., IPR2016-01245 (PTAB) | June 22, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
| Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., 16-3722 (D.N.J.) | June 23, 2016 | Hon. Renee Marie Bumb | Emtriva® (emtricitabine capsules) |
6,642,245
6,703,396
|
| Mylan Pharms., Inc. v. Research Corp. Technologies, Inc., IPR2016-01248 (PTAB) | June 23, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
| BTG Int'l Ltd. v. Glenmark Pharms. Inc., USA, 16-3743 (D.N.J.) | June 24, 2016 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Apotex Inc. v. Osi Pharms., Inc., IPR2016-01284 (PTAB) | June 28, 2016 | N/A | Tarceva® (erlotinib hydrochloride tablets) | 6,900,221 |
| Genzyme Corp. v. Zydus Pharms. (USA) Inc., 16-0540 (D. Del.) | June 29, 2016 | Hon. Gregory M. Sleet | Mozobil® (plerixafor for injection) |
7,897,590
6,987,102
|
| Janssen Pharmaceutica N.V. v. Xellia Pharms ApS, 16-0554 (D. Del.) | June 29, 2016 | Hon. Leonard P. Stark | Sporanox® (voriconazole for injection) | 6,407,079 |
| Genzyme Corp. v. Amneal Pharms. LLC, 16-3892 (D.N.J.) | June 29, 2016 | Hon. Stanley R. Chesler | Clolar® (clofarabine for injection) | 5,661,136 |
| Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01316 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 6,774,122 |
| Argentum Pharms. LLC v. Janssen Oncology, Inc., IPR2016-01317 (PTAB) | June 29, 2016 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01324 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 7,456,160 |
| Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01325 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 8,329,680 |
| Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01326 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 8,466,139 |
| Alcon Pharms. Ltd. v. Imprimis Pharms., Inc., 16-0563 (D. Del.) | June 30, 2016 | Hon. Sue L. Robinson | Vigamox® (moxifloxacin hydrochloride ophthalmic solution) |
6,716,830
7,671,070
|
| Genzyme Corp. v. Zydus Pharms. (USA) Inc., 16-3905 (D.N.J.) | June 30, 2016 | Hon. Renee Marie Bumb | Mozobil® (plerixafor for injection) |
7,897,590
6,987,102
|
| Horizon Therapeutics, Inc. v. Par Pharm., Inc., 16-3910 (D.N.J.) | June 30, 2016 | Hon. Robert B. Kugler | Ravicti® (glycerol phenylbutyrate oral solution) |
9,095,559
9,254,278
9,326,966
|
| Mylan Pharms., Inc. v. Janssen Oncology, Inc., IPR2016-01332 (PTAB) | June 30, 2016 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Wockhardt Bio AG v. Eli Lilly and Co., IPR2016-01335 (PTAB) | June 30, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Wockhardt Bio AG v. Eli Lilly and Co., IPR2016-01337 (PTAB) | June 30, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
